Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTyratech Regulatory News (TYR)

  • There is currently no data for TYR

Arysta Milestone Payments

10 Jan 2008 07:00

XL TechGroup, Inc.10 January 2008 Press Release 10 January 2008 XL TechGroup, Inc. ("XL TechGroup" or "the Company") TyraTech receives Arysta LifeScience milestone payments XL TechGroup (AIM: XLT), the creator of companies that solve identified, globalunmet market needs, is pleased to advise that its portfolio company, TyraTechInc. (AIM: TYR) ("TyraTech"), the pioneer of safer, effective and naturalpesticide products, has achieved development and financial milestones withArysta LifeScience Corporation ("Arysta"), as part of its 2006 exclusive globallicensing and co-development agreement to manufacture and market a number ofinsecticide products for certain horticultural markets. The milestone payments relate to achieving specific insecticide efficacy andcost targets for TyraTech Natural products in two of the licensed applications.Field testing for the lead product prototypes has been underway since late 2006,when an exclusivity payment was received. Dr John Scott, CEO of XL TechGroup, said: "Many horticultural pests havedeveloped resistance to traditional insecticides. As a result, the growingworldwide insecticide market is looking for safe, natural solutions that work,and TyraTech is perfectly positioned to bring its unique technology andexperience to bear. The Arysta partnership represents just one element of thebroad range of applications and markets for TyraTech's technologies. We arepleased with TyraTech's continuing progress in implementing its businessstrategy to plan, and we look forward to further positive developments over thecoming months." - Ends - For further information: XL TechGroup Inc.John Scott / Harold Gubnitsky Tel: +1 321 409 7403hgubnitsky@xltg.comChris Munden, Director of Investor Relations Tel: +44 (0) 20 7398 7720cmunden@xltg.com www.xltechgroup.com Nomura Code SecuritiesRichard Potts, Corporate Finance Tel: +44 (0) 20 7776 1200 www.nomuracode.com XL TechGroup media enquiries:Abchurch CommunicationsHeather Salmond / Gareth Mead Tel: +44 (0) 20 7398 7700heather.salmond@abchurch-group.com www.abchurch-group.com NOTES TO EDITORS About XL TechGroup XL TechGroup is in the business of significant value creation. Working withmajor international corporate and technology partners such as AES, Procter &Gamble and leading universities, XL TechGroup first identifies global unmetmarket needs and then targets and exploits these by the systematic creation ofsuccessful, disruptive technology businesses. These new companies are builtfrom scratch, and are then managed, developed and funded by XL TechGroup throughto the point of a trade sale or a stock market listing. XL TechGroup's unique and proven methodology selects the best opportunities inorder to create one-to-two new companies annually, where each company isexpected to achieve a realisable valuation of at least US$400 million withinfour years from its creation. It is XL TechGroup's aim to deliver significantshareholder distributions at the final exit from each company. XL TechGroup's companies to date are: • PetroAlgae LLC (www.petroalgae.com) • TyraTech Inc. (AIM: TYR, www.tyratech.com) • DxTech LLC (www.dxtech.com) • QuoNova LLC (www.quonova.com) • AgCert International plc (LSE: AGC, www.agcert.com) XL TechGroup has also established GenXL LLC as a joint venture to capture thevalue of those prospects that do not fully meet XL TechGroup's US$400 million,four year criteria but still demonstrate considerable potential worth. Over andabove XL TechGroup's core business model, GenXL has announced its firstinvestments and is reviewing a flow of opportunities from both XL TechGroup andGEN3 in order to generate new companies, standalone product lines and technologylicensing opportunities or an appropriate mix of these. For further information, see www.xltechgroup.com. About TyraTech, Inc. TyraTech is pioneering a new class of highly effective, pesticides andanti-parasitic compounds to address global agriculture, horticulture, functionalfoods, healthcare and veterinary markets. Using a revolutionary chemoreceptorscreening process, TyraTech has identified proprietary blends of natural oilsthat stimulate the reactions and biological behaviour of insects and parasitesso that they can be effectively repelled or killed. TyraTech's technologyprevents the development of resistance and avoids the environmental concerns andhuman health risks of chemical solutions whilst still being at least, if notmore, effective. The Company's products have been validated through strong partnerships withmultinational conglomerates operating within a growing US$23 billion worldwidemarket that is being increasingly driven by environmental legislation andend-user demand. TyraTech continues to develop new product applications based on safe, naturalingredients with a broad range of partners around the world. www.tyratech.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
24th Sep 20157:00 amRNSHalf Yearly Report
2nd Sep 20157:00 amRNSMigration of shares
6th Aug 20157:00 amRNSMigration of Shares
30th Jul 20154:38 pmRNSResult of AGM
3rd Jul 20155:04 pmRNSMigration of Shares
22nd Jun 20157:00 amRNSFinal Results
10th Jun 20152:22 pmRNSMigration of Shares
26th May 20157:01 amRNSSmartPak launches OutSmart insect repellent
21st May 20155:45 pmRNSMigration of Shares
22nd Apr 20157:00 amRNSDirector's Dealings
20th Apr 20157:00 amRNSEnvance LLC amended: Sharpened strategic focus
9th Apr 20151:14 pmRNSMigration of Shares
8th Apr 20157:00 amRNSListing with Walgreens in the USA
27th Mar 20159:41 amRNSMigration of Shares and Exercise of SARs
25th Mar 20157:00 amRNSVamousse now distributed by CVS in the USA
3rd Mar 20157:00 amRNSVamousse now listed by the top 3 distributors, USA
25th Feb 20157:00 amRNSLloyds and Day Lewis Pharmacy listings
16th Feb 20155:01 pmRNSDirector's Dealings
2nd Feb 20157:00 amRNSVamousse at Walmart and Cardinal Health USA
26th Jan 20157:00 amRNSInnovators and Investors Forum, London
15th Jan 20157:00 amRNSAppointment of Chief Financial Officer & Treasurer
2nd Dec 20147:00 amRNSTrading Update
1st Oct 20147:00 amRNSExercise of Warrants
29th Sep 20147:00 amRNSInterim Results
27th Aug 20147:00 amRNSVamousse products coming to Sainsbury's and Tesco
8th Aug 201410:30 amRNSHolding(s) in Company
5th Aug 201410:29 amRNSHolding(s) in Company
1st Aug 20145:49 pmRNSHolding(s) in Company
1st Aug 20142:40 pmRNSHolding(s) in Company
28th Jul 20145:35 pmRNSResult of Special Meeting & Director Shareholdings
16th Jul 20147:00 amRNSResult of AGM
16th Jul 20147:00 amRNSPlacing to raise £3.5m and launch of UK Vamousse
26th Jun 20147:00 amRNSFinal Results
22nd May 20144:02 pmRNSMigration of Shares
19th May 20146:15 pmRNSMigration of Shares
19th May 20147:00 amRNSVamousse product line available online across USA
30th Apr 20147:00 amRNSNatunex product launched across USA
24th Apr 20147:00 amRNSUSA Pest Control Patents Secured
8th Apr 20146:10 pmRNSDirector's Dealings
7th Apr 20144:41 pmRNSDirector's Dealings
1st Apr 20147:00 amRNSVamousse at over 4,000 Walmart Stores in USA
7th Mar 20147:00 amRNSMigration of Shares
6th Mar 201411:48 amRNSHolding(s) in Company
6th Mar 20147:00 amRNSAward of Share Options
24th Feb 20147:00 amRNSProposed Migration of Shares
18th Feb 20143:38 pmRNSResult of Special Meeting
13th Feb 20149:47 amRNSHolding(s) in Company
31st Jan 20144:26 pmRNSProposed Placing
23rd Jan 20145:58 pmRNSHolding(s) in Company
20th Jan 20147:00 amRNSHead-Lice Preventative Shampoo Coming to US Market

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.